GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

daptomycin   Click here for help

GtoPdb Ligand ID: 10904

Synonyms: Cubicin® | LY-146032 | LY146032
Approved drug
daptomycin is an approved drug (FDA (2003), EMA (2006))
Compound class: Natural product
Comment: Daptomycin is a cyclic lipopeptide antibacterial with broad-spectrum activity against Gram-positive bacteria [2]. It is a bacterial metabolite that was isolated from Streptomyces roseosporus [1]. Daptomycin rapidly depolarizes the bacterial cell membrane which disrupts DNA, RNA and protein synthesis and results in cell death.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 42
Hydrogen bond donors 22
Rotatable bonds 39
Topological polar surface area 702.02
Molecular weight 1619.71
XLogP 1.92
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NCCC[C@@H]1NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2c[nH]c3c2cccc3)NC(=O)CCCCCCCCC)CC(=O)N)CC(=O)O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC(=O)O)C)CC(=O)O)CO)[C@@H](CC(=O)O)C)CC(=O)c1ccccc1N
Isomeric SMILES NCCC[C@@H]1NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2c[nH]c3c2cccc3)NC(=O)CCCCCCCCC)CC(=O)N)CC(=O)O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC(=O)O)C)CC(=O)O)CO)[C@@H](CC(=O)O)C)CC(=O)c1ccccc1N
InChI InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
InChI Key DOAKLVKFURWEDJ-RWDRXURGSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Debono M, Barnhart M, Carrell CB, Hoffmann JA, Occolowitz JL, Abbott BJ, Fukuda DS, Hamill RL, Biemann K, Herlihy WC. (1987)
A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation.
J Antibiot (Tokyo), 40 (6): 761-77. [PMID:3610833]
2. Eliopoulos GM, Willey S, Reiszner E, Spitzer PG, Caputo G, Moellering Jr RC. (1986)
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
Antimicrob Agents Chemother, 30 (4): 532-5. [PMID:3024560]
3. Ge Y, Biek D, Talbot GH, Sahm DF. (2008)
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
Antimicrob Agents Chemother, 52 (9): 3398-407. [PMID:18625769]
4. World Health Organization. Regional Office for Europe. 
Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for Children (EMLc): Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics.
Accessed on 08/05/2026. Modified on 08/05/2026. https://iris.who.int/items/e2f730ae-f66f-44d6-bc24-164fe79164ec